Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States
To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population. Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngolog...
Gespeichert in:
| Veröffentlicht in: | Otolaryngology-head and neck surgery 2007-06, Vol.136 (6), p.992-997 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 997 |
|---|---|
| container_issue | 6 |
| container_start_page | 992 |
| container_title | Otolaryngology-head and neck surgery |
| container_volume | 136 |
| creator | O, Teresa M. Yu, Guopei Hu, Kenneth Li, James C.L. |
| description | To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population.
Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed.
Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent.
NPC screening in a high-risk, nonendemic population using EBV-specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy.
The development of a cost-effective NPC screening strategy in a high-risk, nonendemic population in the United States. |
| doi_str_mv | 10.1016/j.otohns.2006.11.053 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70562584</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1016_j.otohns.2006.11.053</sage_id><els_id>S0194599806035832</els_id><sourcerecordid>70562584</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5214-e7c27afb6a66cf051360836257a7a847ea075a574a2e49c67c597aedb5f00d123</originalsourceid><addsrcrecordid>eNqNkM1q3DAURkVpaKZJ36AUrbqzK3n0Y0MpTNKkKYQkkGYt7sjXMxpsaSrZKXn7avBAd21X2nznoHsIec9ZyRlXn3ZlGMPWp7JiTJWcl0wuX5EFZ40uVM31a7JgvBGFbJr6lLxNacfyUGn9hpxyLYVuGrEg_qGHNAC92qcRnS8uIEb67OKUqBuGyYdNH9ZT7zxdUfAt_Xq3ol2I1EMK-y3EF79B6KmFaJ0PWZRsRPTOb2hmxi3SJ-9GbOnjCCOmc3LSQZ_w3fE9I0_XVz8ub4rb-2_fL1e3hZUVFwVqW2no1gqUsh2TfKlYvVSV1KChFhqBaQlSC6hQNFZpKxsN2K5lx1jLq-UZ-Th79zH8nDCNZnDJYt-DxzAlo5nMtlrkoZiHNoaUInZmH92Q7zKcmUNnszNzZ3PobDg3uXPGPhz903rA9g90DJsHn-fBL9fjy39Jzf3N3cV1lQ894HzGE2zQ7MIUfc71rz99mRnMYZ8dRpOsQ2-xdRHtaNrg_i74DY_btI0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70562584</pqid></control><display><type>article</type><title>Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><source>Wiley Online Library All Journals</source><source>Alma/SFX Local Collection</source><creator>O, Teresa M. ; Yu, Guopei ; Hu, Kenneth ; Li, James C.L.</creator><creatorcontrib>O, Teresa M. ; Yu, Guopei ; Hu, Kenneth ; Li, James C.L.</creatorcontrib><description>To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population.
Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed.
Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent.
NPC screening in a high-risk, nonendemic population using EBV-specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy.
The development of a cost-effective NPC screening strategy in a high-risk, nonendemic population in the United States.</description><identifier>ISSN: 0194-5998</identifier><identifier>EISSN: 1097-6817</identifier><identifier>DOI: 10.1016/j.otohns.2006.11.053</identifier><identifier>PMID: 17547994</identifier><language>eng</language><publisher>Los Angeles, CA: Mosby, Inc</publisher><subject>Adult ; Antibodies, Viral - blood ; DNA, Viral - blood ; Epstein-Barr Virus Infections - diagnosis ; Epstein-Barr Virus Infections - virology ; Female ; Herpesvirus 4, Human - genetics ; Herpesvirus 4, Human - immunology ; Hospitals, Teaching ; Humans ; Immunoglobulin A - blood ; Male ; Mass Screening ; Middle Aged ; Nasopharyngeal Neoplasms - diagnosis ; Nasopharyngeal Neoplasms - virology ; New York City ; Prospective Studies ; Risk Factors ; Sensitivity and Specificity</subject><ispartof>Otolaryngology-head and neck surgery, 2007-06, Vol.136 (6), p.992-997</ispartof><rights>2007 American Academy of Otolaryngology–Head and Neck Surgery Foundation</rights><rights>2007 SAGE Publications</rights><rights>2007 American Association of Otolaryngology‐Head and Neck Surgery Foundation (AAO‐HNSF)</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5214-e7c27afb6a66cf051360836257a7a847ea075a574a2e49c67c597aedb5f00d123</citedby><cites>FETCH-LOGICAL-c5214-e7c27afb6a66cf051360836257a7a847ea075a574a2e49c67c597aedb5f00d123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1016/j.otohns.2006.11.053$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1016/j.otohns.2006.11.053$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,1417,21819,27924,27925,43621,43622,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17547994$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>O, Teresa M.</creatorcontrib><creatorcontrib>Yu, Guopei</creatorcontrib><creatorcontrib>Hu, Kenneth</creatorcontrib><creatorcontrib>Li, James C.L.</creatorcontrib><title>Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States</title><title>Otolaryngology-head and neck surgery</title><addtitle>Otolaryngol Head Neck Surg</addtitle><description>To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population.
Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed.
Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent.
NPC screening in a high-risk, nonendemic population using EBV-specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy.
The development of a cost-effective NPC screening strategy in a high-risk, nonendemic population in the United States.</description><subject>Adult</subject><subject>Antibodies, Viral - blood</subject><subject>DNA, Viral - blood</subject><subject>Epstein-Barr Virus Infections - diagnosis</subject><subject>Epstein-Barr Virus Infections - virology</subject><subject>Female</subject><subject>Herpesvirus 4, Human - genetics</subject><subject>Herpesvirus 4, Human - immunology</subject><subject>Hospitals, Teaching</subject><subject>Humans</subject><subject>Immunoglobulin A - blood</subject><subject>Male</subject><subject>Mass Screening</subject><subject>Middle Aged</subject><subject>Nasopharyngeal Neoplasms - diagnosis</subject><subject>Nasopharyngeal Neoplasms - virology</subject><subject>New York City</subject><subject>Prospective Studies</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><issn>0194-5998</issn><issn>1097-6817</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1q3DAURkVpaKZJ36AUrbqzK3n0Y0MpTNKkKYQkkGYt7sjXMxpsaSrZKXn7avBAd21X2nznoHsIec9ZyRlXn3ZlGMPWp7JiTJWcl0wuX5EFZ40uVM31a7JgvBGFbJr6lLxNacfyUGn9hpxyLYVuGrEg_qGHNAC92qcRnS8uIEb67OKUqBuGyYdNH9ZT7zxdUfAt_Xq3ol2I1EMK-y3EF79B6KmFaJ0PWZRsRPTOb2hmxi3SJ-9GbOnjCCOmc3LSQZ_w3fE9I0_XVz8ub4rb-2_fL1e3hZUVFwVqW2no1gqUsh2TfKlYvVSV1KChFhqBaQlSC6hQNFZpKxsN2K5lx1jLq-UZ-Th79zH8nDCNZnDJYt-DxzAlo5nMtlrkoZiHNoaUInZmH92Q7zKcmUNnszNzZ3PobDg3uXPGPhz903rA9g90DJsHn-fBL9fjy39Jzf3N3cV1lQ894HzGE2zQ7MIUfc71rz99mRnMYZ8dRpOsQ2-xdRHtaNrg_i74DY_btI0</recordid><startdate>200706</startdate><enddate>200706</enddate><creator>O, Teresa M.</creator><creator>Yu, Guopei</creator><creator>Hu, Kenneth</creator><creator>Li, James C.L.</creator><general>Mosby, Inc</general><general>SAGE Publications</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>8BM</scope></search><sort><creationdate>200706</creationdate><title>Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States</title><author>O, Teresa M. ; Yu, Guopei ; Hu, Kenneth ; Li, James C.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5214-e7c27afb6a66cf051360836257a7a847ea075a574a2e49c67c597aedb5f00d123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>Antibodies, Viral - blood</topic><topic>DNA, Viral - blood</topic><topic>Epstein-Barr Virus Infections - diagnosis</topic><topic>Epstein-Barr Virus Infections - virology</topic><topic>Female</topic><topic>Herpesvirus 4, Human - genetics</topic><topic>Herpesvirus 4, Human - immunology</topic><topic>Hospitals, Teaching</topic><topic>Humans</topic><topic>Immunoglobulin A - blood</topic><topic>Male</topic><topic>Mass Screening</topic><topic>Middle Aged</topic><topic>Nasopharyngeal Neoplasms - diagnosis</topic><topic>Nasopharyngeal Neoplasms - virology</topic><topic>New York City</topic><topic>Prospective Studies</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>O, Teresa M.</creatorcontrib><creatorcontrib>Yu, Guopei</creatorcontrib><creatorcontrib>Hu, Kenneth</creatorcontrib><creatorcontrib>Li, James C.L.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>ComDisDome</collection><jtitle>Otolaryngology-head and neck surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>O, Teresa M.</au><au>Yu, Guopei</au><au>Hu, Kenneth</au><au>Li, James C.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States</atitle><jtitle>Otolaryngology-head and neck surgery</jtitle><addtitle>Otolaryngol Head Neck Surg</addtitle><date>2007-06</date><risdate>2007</risdate><volume>136</volume><issue>6</issue><spage>992</spage><epage>997</epage><pages>992-997</pages><issn>0194-5998</issn><eissn>1097-6817</eissn><abstract>To examine the Epstein-Barr virus (EBV) IgA and DNA assays as a screening tool for nasopharyngeal carcinoma (NPC) in a nonendemic US population.
Prospective study performed at a teaching hospital in New York City. There were two groups of 155 patients: new NPC patients and controls. An otolaryngologic examination and serial blood testing for serologic markers were performed.
Sensitivity and specificity of EBV IgA and DNA assays were determined. Screening scenarios involving series and parallel testing were evaluated to determine economic feasibility. Series testing provided a sensitivity, specificity, and positive and negative predictive values of 90.6, 93.5, 78.4, and 97.5 percent, respectively. Parallel testing increased the sensitivity to 100 percent.
NPC screening in a high-risk, nonendemic population using EBV-specific serologic markers is effective. Series testing is a statistically sound and economically feasible strategy.
The development of a cost-effective NPC screening strategy in a high-risk, nonendemic population in the United States.</abstract><cop>Los Angeles, CA</cop><pub>Mosby, Inc</pub><pmid>17547994</pmid><doi>10.1016/j.otohns.2006.11.053</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0194-5998 |
| ispartof | Otolaryngology-head and neck surgery, 2007-06, Vol.136 (6), p.992-997 |
| issn | 0194-5998 1097-6817 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70562584 |
| source | MEDLINE; SAGE Complete A-Z List; Wiley Online Library All Journals; Alma/SFX Local Collection |
| subjects | Adult Antibodies, Viral - blood DNA, Viral - blood Epstein-Barr Virus Infections - diagnosis Epstein-Barr Virus Infections - virology Female Herpesvirus 4, Human - genetics Herpesvirus 4, Human - immunology Hospitals, Teaching Humans Immunoglobulin A - blood Male Mass Screening Middle Aged Nasopharyngeal Neoplasms - diagnosis Nasopharyngeal Neoplasms - virology New York City Prospective Studies Risk Factors Sensitivity and Specificity |
| title | Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T16%3A22%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20Epstein-Barr%20virus%20immunoglobulin%20A%20and%20DNA%20for%20nasopharyngeal%20carcinoma%20screening%20in%20the%20United%20States&rft.jtitle=Otolaryngology-head%20and%20neck%20surgery&rft.au=O,%20Teresa%20M.&rft.date=2007-06&rft.volume=136&rft.issue=6&rft.spage=992&rft.epage=997&rft.pages=992-997&rft.issn=0194-5998&rft.eissn=1097-6817&rft_id=info:doi/10.1016/j.otohns.2006.11.053&rft_dat=%3Cproquest_cross%3E70562584%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70562584&rft_id=info:pmid/17547994&rft_sage_id=10.1016_j.otohns.2006.11.053&rft_els_id=S0194599806035832&rfr_iscdi=true |